BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript

Ugur Sahin: Yeah. This is a good question, indeed. Indeed, the question is about HER2 low, one plus, two plus or even ultra-low or even negative. So we are considering all patient cohorts in our trial design and will make a decision on the patient population to be enrolled and the patient population to be analyzed later on for the upcoming trials and will most likely report about the clinical trial design end of this year.

Yifeng Liu: Thanks.

Operator: Thank you. We will now take our final question for today. And your final question comes from the line of Suzanne Van Voorthuizen from VLK. Please go ahead.

Suzanne Van Voorthuizen: Hi, there. This is Suzanne from VLK. Thanks for taking my question, which relates to business development and M&A. Last year you were fairly active on the deal making front. So can you give [Technical Difficulty] what we could expect going forward for this and next year? You have a lot of cash on hand, but also a lot of projects to run and many moving parts on the profitability side. So I was wondering if you’re continuing to pursue similar deals and assets as previously, or does your appetite change? Thank you.

Ryan Richardson: Yes. Thanks, Suzanne. I think our focus this year is more on clinical execution. That said, we will be opportunistic and if — we’re open to synergistic assets, but I think you can expect the general level of activity in terms of number of deals to be decreased this year.

Suzanne Van Voorthuizen: Got it.

Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.